Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

In their zeal to "Make America Healthy Again," top Trump administration officials depict patients and the doctors who treat ...

(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Incannex's IHL-42X showed significant efficacy in Phase 2 sleep apnea trial, with strong AHI reduction, improved sleep, and ...

Diabetes drugs from Eli Lilly and Novo Nordisk, such as Mounjaro, Zepbound, Ozempic, and Wegovy, are expanding beyond ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. Eli Lilly's recent popularity is due in no small measure to its plunge into the highly ...

In April, Danish drugmaker Novo Nordisk formed what was supposed to be a long-term collaboration to promote its weight-loss ...

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

Amazon opened its first Michigan pharmacy this week in a bid to dominate the growing prescription delivery sector. The online ...